tetano
Editor, Senior Moderator
Cureus
. 2021 Sep 1;13(9):e17637.
doi: 10.7759/cureus.17637. eCollection 2021 Sep.
Intracerebral Hemorrhage and Thrombocytopenia After AstraZeneca COVID-19 Vaccine: Clinical and Diagnostic Challenges of Vaccine-Induced Thrombotic Thrombocytopenia
Floor N H Wilting[SUP] 1 [/SUP], Angela M M Kotsopoulos[SUP] 2 [/SUP], Anouk C M Platteel[SUP] 3 [/SUP], Jos A H van Oers[SUP] 2 [/SUP]
Affiliations
Abstract
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a prothrombotic disorder, which has been described as a rare adverse effect of the adenoviral-vectored coronavirus disease 2019 (COVID-19) vaccines. The diagnosis is confirmed by the detection of anti-platelet factor 4 (PF4) antibodies by enzyme-linked immunosorbent assay (ELISA) or functional assay in individuals with the appropriate clinical history. Here, we report a case of a patient who presented with a severe intracerebral hemorrhage and thrombocytopenia 14 days after receiving the first dose of the Oxford-AstraZeneca COVID-19 vaccine, with negative PF4/heparin antibodies tested with ELISA, but positive heparin-induced platelet activation assay (HIPAA).
Keywords: astrazeneca vaccine; chadox1 ncov-19; covid-19; heparin; intracerebral hemorrhage; sars-cov-2; thrombocytopenia; thrombosis.
. 2021 Sep 1;13(9):e17637.
doi: 10.7759/cureus.17637. eCollection 2021 Sep.
Intracerebral Hemorrhage and Thrombocytopenia After AstraZeneca COVID-19 Vaccine: Clinical and Diagnostic Challenges of Vaccine-Induced Thrombotic Thrombocytopenia
Floor N H Wilting[SUP] 1 [/SUP], Angela M M Kotsopoulos[SUP] 2 [/SUP], Anouk C M Platteel[SUP] 3 [/SUP], Jos A H van Oers[SUP] 2 [/SUP]
Affiliations
- PMID: 34646685
- PMCID: PMC8486363
- DOI: 10.7759/cureus.17637
Abstract
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a prothrombotic disorder, which has been described as a rare adverse effect of the adenoviral-vectored coronavirus disease 2019 (COVID-19) vaccines. The diagnosis is confirmed by the detection of anti-platelet factor 4 (PF4) antibodies by enzyme-linked immunosorbent assay (ELISA) or functional assay in individuals with the appropriate clinical history. Here, we report a case of a patient who presented with a severe intracerebral hemorrhage and thrombocytopenia 14 days after receiving the first dose of the Oxford-AstraZeneca COVID-19 vaccine, with negative PF4/heparin antibodies tested with ELISA, but positive heparin-induced platelet activation assay (HIPAA).
Keywords: astrazeneca vaccine; chadox1 ncov-19; covid-19; heparin; intracerebral hemorrhage; sars-cov-2; thrombocytopenia; thrombosis.